Flag of the European Union EU Clinical Trials Register Help

Clinical trials for eudract

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    227 result(s) found for: eudract. Displaying page 10 of 12.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next»
    EudraCT Number: 2011-001318-32 Sponsor Protocol Number: P261-401 Start Date*: 2011-11-17
    Sponsor Name:Upsher-Smith Laboratories, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intranasal Midazolam (USL261) in the Outpatient Treatment of Subjects with Seizure Clusters ARTEMIS-1: Acute Rescu...
    Medical condition: epilepsy
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10015052 Epileptic seizure LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000236-27 Sponsor Protocol Number: VEG105281 Start Date*: 2006-12-15
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Phase II, Open-Label, Randomized, Multicenter Trial of Pazopanib (GW786034) in Combination with Lapatinib (GW572016) Compared to Pazopanib Montherapy and Lapatinib Monotherapy in Subjects with FI...
    Medical condition: Patients with FIGO Stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10008229 Cervical cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) BE (Completed) IE (Completed) FR (Completed) EE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-023349-32 Sponsor Protocol Number: DB2113373 Start Date*: 2011-05-26
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily via a N...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) GR (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-005123-42 Sponsor Protocol Number: VX06-950-107 Start Date*: 2007-03-28
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Rollover Protocol of Telaprevir (VX-950) in Combination with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Enrolled in the Control Group (Group A) of Study VX06-950-106 Wh...
    Medical condition: Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019744 Hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) GB (Completed) FR (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-004556-71 Sponsor Protocol Number: P05514 Start Date*: 2009-05-25
    Sponsor Name:Schering-Plough Research Institute, A Division of Schering Corporation
    Full Title: Estudio de un solo grupo para facilitar tratamiento con boceprevir a sujetos con el genotipo 1 del virus de la hepatitis C crónica que no han respondido a peginterferón/ribavirina en estudios previ...
    Medical condition: Hepatitis C Crónica
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    9.1 10019744 PT
    9.1 10021881 SOC
    9.1 10019805 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) DE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004215-13 Sponsor Protocol Number: CCC844 Start Date*: 2017-12-29
    Sponsor Name:The Clatterbridge Cancer Centre NHS Foundation
    Full Title: Randomised Phase II Trial of Cediranib and Olaparib Maintenance in Advanced/Recurrent Cervical Cancer (COMICE)
    Medical condition: Advanced recurrent and metastatic cervical cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10008231 Cervical cancer recurrent LLT
    20.0 100000004864 10008235 Cervical cancer stage III LLT
    20.0 100000004864 10008236 Cervical cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-005107-26 Sponsor Protocol Number: 242-07-208 Start Date*: 2009-04-08
    Sponsor Name:Otsuka Pharmaceutical Development and Commercialization, Inc.
    Full Title: A Phase 2, Multi-center, Uncontrolled, Open-label Trial to Evaluate Safety, tolerability, and Efficacy of Orally Administered OPC-67683 as 100 mg BID with optional titration to 200 mg BID for up t...
    Medical condition: Pulmonary Multidrug-resistant Tuberculosis (MDR TB)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037440 Pulmonary tuberculosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LV (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000656-42 Sponsor Protocol Number: 3102-006-10 Start Date*: 2011-04-08
    Sponsor Name:MSD Finland Oy
    Full Title: A 66-Week Extension to: A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding, Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients with Type 2 Diabetes Mellitus and Ina...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002838-38 Sponsor Protocol Number: M05-782 Start Date*: 2007-03-14
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Phase 1/2 Study Evaluating the Safety and Efficacy of ABT-751 in Combination with Docetaxel Versus Docetaxel Alone in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer
    Medical condition: Advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed following one or more chemotherapy regimens.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059515 Non-small cell lung cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000219-24 Sponsor Protocol Number: 3082A-101342 Start Date*: 2005-04-28
    Sponsor Name:Wyeth Pharmaceuticals
    Full Title: A multicentre study to describe the immunogenic epitope(s) of factor VIII in previously treated patients with congenital haemophilia A who develop de novo factor VIII inhibitors while receiving fac...
    Medical condition: Haemophilia A is an X-linked recessive clotting disorder in which the clotting factor, factor VIII (FVIII), is deficient or inactive. Patients with low levels of FVIII have an increased tendency t...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed) DE (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004774-27 Sponsor Protocol Number: ART108053 Start Date*: 2007-03-14
    Sponsor Name:GlaxoSmithKline Research & Development Ltd.
    Full Title: Comparison of ARIXTRA™ in lower LImb Superficial Thrombophlebitis with placebO (CALISTO). An International, Multicentre, Randomised, Double-blind, Placebo-controlled, Two-parallel Group, Phase III...
    Medical condition: Superficial Thrombophlebitis (also known as superficial vein thrombosis)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10042557 Superficial thrombophlebitis of leg LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) EE (Completed) HU (Completed) LV (Completed) GR (Completed) FR (Completed) SK (Completed) CZ (Completed) IT (Completed) GB (Completed) BG (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-003408-65 Sponsor Protocol Number: Start Date*: 2016-08-26
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian
    Full Title: Ulipristal acetate versus conventional management of heavy menstrual bleeding (HMB; including uterine fibroids): a randomised controlled trial and exploration of mechanism of action (UCON trial)
    Medical condition: Heavy menstrual bleeding
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10046784 Uterine fibroids LLT
    18.0 10038604 - Reproductive system and breast disorders 10027313 Menorrhagia PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2017-002300-27 Sponsor Protocol Number: SPON1529-16 Start Date*: 2019-09-13
    Sponsor Name:Cardiff University
    Full Title: Phase 1b/II Trial of Checkpoint Inhibitor (Pembrolizumab an Anti PD-1 Antibody) Plus Standard IMRT in HPV Induced Stage III Squamous Cell Carcinoma of Anus
    Medical condition: Locally advanced (stage IIIA/B, T3/T4, any N,M0) anal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061424 Anal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-002762-44 Sponsor Protocol Number: RG-16-040 Start Date*: 2018-05-01
    Sponsor Name:University of Birmingham
    Full Title: A phase I/II study evaluating the safety and activity of Pegylated recombinant human Arginase (BCT-100) in Relapsed/refractory cancers of Children and young adults
    Medical condition: Relpased/refractory paeditaric cancers: Leukaemias Sarcoma Neuroblastoma High grade glioma (brain cancers)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000830 Acute leukaemia PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065443 Malignant glioma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039494 Sarcoma NOS LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-004403-14 Sponsor Protocol Number: BCX9930-203 Start Date*: 2021-11-11
    Sponsor Name:BioCryst Pharmaceuticals Inc
    Full Title: A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of Paroxysmal Noct...
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10034042 Paroxysmal nocturnal haemoglobinuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) LT (Completed) CZ (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001926-71 Sponsor Protocol Number: LDX0319 Start Date*: Information not available in EudraCT
    Sponsor Name:Dompe farmaceutici s.p.a.
    Full Title: A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the effect and safety of 400 mg twice a day oral ladarixin in patients with recent onset type 1 diabetes and a l...
    Medical condition: Recent onset Type 1 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) SI (Completed) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-001402-92 Sponsor Protocol Number: AVA102670 Start Date*: 2006-09-06
    Sponsor Name:GlaxoSmithKline R&D Limited
    Full Title: A 54-week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to acetylcholinesterase in...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) GB (Completed) NL (Completed) FI (Completed) BE (Completed) CZ (Completed) SI (Completed) SK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-000470-78 Sponsor Protocol Number: TRA102537 Start Date*: 2006-10-30
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A randomized, double-blind, placebo-controlled phase III study, to evaluate the efficacy, safety and tolerability of eltrombopag olamine (SB-497115-GR), a thrombopoietin receptor agonist, administe...
    Medical condition: Idiopathic thrombocytopenic purpura (ITP)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10051057 Idiopathic thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FI (Completed) DK (Completed) FR (Completed) AT (Completed) CZ (Completed) SK (Completed) DE (Completed) GR (Completed) IT (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-002633-20 Sponsor Protocol Number: A4M105038 Start Date*: 2006-11-17
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months' Administration of Firategrast (150 – 1200mg twice dail...
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) FI (Completed) FR (Completed) AT (Completed) IT (Completed) LT (Prematurely Ended) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-003200-48 Sponsor Protocol Number: EP0091 Start Date*: 2018-04-09
    Sponsor Name:UCB Biopharma SPRL
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects with Drug- Res...
    Medical condition: Focal-Onset Seizures
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10065337 Focal epilepsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) HU (Completed) CZ (Completed) BE (Completed) ES (Completed) FR (Completed) BG (Completed) LT (Completed) SK (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 13 06:24:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA